Can a new antibody help the immune system fight advanced cancers?
NCT ID NCT06719362
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given alone or combined with other cancer treatments like pembrolizumab (Keytruda), chemotherapy, or radiation. About 110 adults with various advanced solid tumors, including glioblastoma, will take part. The focus is on finding the right dose and watching for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental antibody called M3T01, given alone or with pembrolizumab (Keytruda) and other standard therapies
- What this could lead to
- If safe and effective, M3T01 could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
- What could go wrong
- This is a very early, first-in-human trial, so safety and dosing are still being determined. The drug may not work or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Providence Portland Cancer Institute - Franz Clinic
RECRUITINGPortland, Oregon, 97213, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
- Can a cancer vaccine train the body to fight advanced tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?